The potential of cell-based therapy for diabetes and diabetes-related vascular complications

Current Diabetes Reports

Volumn 14, Issue 3, 2014, Pages

  Liew, Aaron ^a   O'Brien, Timothy ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

Beta cell replacement; Cell therapy; Diabetes mellitus; Vascular complications

Indexed keywords

ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CELL THERAPY; CLINICAL STUDY; CLINICAL TRIAL (TOPIC); CORD BLOOD STEM CELL TRANSPLANTATION; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC CARDIOMYOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; EMBRYONIC STEM CELL; GLUCOSE BLOOD LEVEL; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; LYMPHOCYTE; LYMPHOCYTE TRANSFER; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; MONONUCLEAR CELL; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL; PANCREAS ISLET TRANSPLANTATION; PERIPHERAL VASCULAR DISEASE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PLURIPOTENT STEM CELL; STEM CELL TRANSPLANTATION; UMBILICAL CORD BLOOD; WOUND HEALING; CYTOLOGY; PATHOLOGY; REVIEW;

DIABETES MELLITUS; DIABETIC ANGIOPATHIES; EMBRYONIC STEM CELLS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; INSULIN-SECRETING CELLS; STEM CELL TRANSPLANTATION;

EID: 84892737760     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-013-0469-6     Document Type: Article

References (99)

1. Lysy PA, Weir GC, Bonner-Weir S. Concise review: pancreas regeneration: recent advances and perspectives. Stem Cells Transl Med. 2012;1:150-9.
2. Narayanan K, Lim VY, Shen J, Tan ZW, Rajendran D, Luo SC, et al. Extracellular matrix-mediated differentiation of human embryonic stem cells: differentiation to insulin-secreting beta cells. Tissue Eng Part A. 2013;20(1-2):424-33. This paper described the method for differentiation of human embryonic stem cells to insulin-secreting cells.
3. Van Hoof D, Liku ME. Directed differentiation of human pluripotent stem cells along the pancreatic endocrine lineage. Methods Mol Biol. 2013;997:127-40. This paper described the method for differentiation of human pluripotent stem cells to insulin-producing cells.
4. Dave SD, Vanikar AV, Trivedi HL. Ex vivo generation of glucose sensitive insulin secreting mesenchymal stem cells derived from human adipose tissue. Indian J Endocrinol Metabol. 2012;16 Suppl 1:S65-9. This paper described the method for differentiation of mesenchymal stem cells to insulin secreting cells.
5. Bruin JE, Rezania A, Xu J, Narayan K, Fox JK, O'Neil JJ, et al. Maturation and function of human embryonic stem cell-derived pancreatic progenitors in macroencapsulation devices following transplant into mice. Diabetologia. 2013;56:1987-98.
6. Lahmy R, Soleimani M, Sanati MH, Behmanesh M, Kouhkan F, Mobarra N. Pancreatic islet differentiation of human embryonic stem cells by microRNA overexpression. J Tissue Eng Regen Med. 2013. doi: 10.1002/term.1787
7. Tanaka H, Tanaka S, Sekine K, Kita S, Okamura A, Takebe T, et al. The generation of pancreatic beta-cell spheroids in a simulated microgravity culture system. Biomaterials. 2013;34:5785-91.
8. Schulz TC, Young HY, Agulnick AD, Babin MJ, Baetge EE, Bang AG, et al. A scalable system for production of functional pancreatic progenitors from human embryonic stem cells. PloS One. 2012;7:e37004.
9. Fujikawa T, Oh SH, Pi L, Hatch HM, Shupe T, Petersen BE. Teratoma formation leads to failure of treatment for type I diabetes using embryonic stem cell-derived insulin-producing cells. Am J Pathol. 2005;166:1781-91. (Pubitemid 40734401)
10. Tuch BE, Hughes TC, Evans MD. Encapsulated pancreatic progenitors derived from human embryonic stem cells as a therapy for insulin-dependent diabetes. Diabetes Metab Rev. 2011;27:928-32.
11. Wang Y, Yang D, Song L, Li T, Yang J, Zhang X, et al. Mifepristone-inducible caspase-1 expression in mouse embryonic stem cells eliminates tumor formation but spares differentiated cells in vitro and in vivo. Stem Cells. 2012;30:169-79.
12. Park KD, Seong SK, Park YM, Choi Y, Park JH, Lee SH, et al. Telomerase reverse transcriptase related with telomerase activity regulates tumorigenic potential of mouse embryonic stem cells. Stem Cells Dev. 2011;20:149-57.
13. Araki R, Uda M, Hoki Y, Sunayama M, Nakamura M, Ando S, et al. Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells. Nature. 2013;494:100-4.
14. Jee J, Jeon H, Hwang D, Sommer P, Park Z, Cechetto J, et al. High content screening for compounds that induce early stages of human embryonic stem cell differentiation. Comb Chem High Throughput Screen. 2012;15:656-65.
15. Schwartz SD, Hubschma~ JP, Heilwell G, Franco-Cardenas V, Pan CK, Ostrick RM, et al. Umbryonic stem cell trials for mqcular degeneration: a preliminary report. Lancet. 2012;379:713-20.
16. Atala A. Human embryonic stem cells: early0hints on safety and efficacy. Lqncet. 2012;379:689-90.
17. Tqkahashi K, Yamanaka S. Inductio~ of pluripotent stem cells from0mouse embryonic and adult fibrorlast cultures by defined factors. Cell. 2006;126:663-76. (Pubitemid 44233629)
18. Zhao XY, Li W, Lv Z, Liu L, Tong M, Hai T, et al. iPS culls produce viable mice through0tetraploid complementation. Nature. 2009;461:86-90.
19. Zhao T, Zhang ZN, Rong Z, Xu Y. Immunogenicity of induced pluripotent stem cells. Nature. 2011;474:212-5.
20. Okano H, Nakamura M, Yoshida K, Okada Y, Tsuji O, Nori S, et al. Steps toward safe cell therapy using induced pluripotent stem cells. Circ Res. 2013;112:523-33.
21. Takahashi K, Okita K, Nakagawa M, Yamanaka S. Induction of pluripotent stem cells from fibroblast cultures. Nat Protoc. 2007;2:3081-9.
22. Ohmine S, Dietz AB, Deeds MC, Hartjes KA, Miller DR, Thatava T, et al. Induced pluripotent stem cells from GMP-grade hematopoietic progenitor cells and mononuclear myeloid cells. Stem Cell Res Ther. 2011;2:46.
23. Fan Y, Hsiung M, Cheng C, Tzanakakis ES. Facile engineering of xeno-free microcarriers for the scalable cultivation of human pluripotent stem cells in stirred suspension. Tissue Eng Part A. 2013. doi: 10.1089/ten.TEA.2013.0219
24. Snarski E, Torosian T, Paluszewska M, Urbanowska E, Milczarczyk A, Jedynasty K, et al. Alleviation of exogenous insulin requirement in type 1 diabetes mellitus after immunoablation and transplantation of autologous hematopoietic stem cells. Pol Arch Med Wewn. 2009;119:422-6.
25. Snarski E, Milczarczyk A, Torosian T, Paluszewska M, Urbanowska E, Krol M, et al. Independence of exogenous insulin following immunoablation and stem cell reconstitution in newly diagnosed diabetes type I. Bone Marrow Transplant. 2011;46:562-6.
26. Li L, Shen S, Ouyang J, Hu Y, Hu L, Cui W, et al. Autologous hematopoietic stem cell transplantation modulates immunocompetent cells and improves beta-cell function in Chinese patients with new onset of type 1 diabetes. J Clin Endocrinol Metabol. 2012;97:1729-36. This prospective, non-randomized, open label trial showed the safety and feasibility of intravenous autologous hematopoietic stem cell therapy in patients with T1DM.
27. Shen S, Li L, Ouyang J, Xu J, Zhu D. Remission induced by autologous hematopoietic stem cell transplantation in one newly diagnosed type 1 diabetes patient with diabetic ketoacidosis: a case report. J Diabetes. 2012;4:359-61.
28. Voltarelli JC, Couri CE, Stracieri AB, Oliveira MC, Moraes DA, Pieroni F, et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA. 2007;297:1568-76. (Pubitemid 46588370)
29. Couri CE, Oliveira MC, Stracieri AB, Moraes DA, Pieroni F, Barros GM, et al. C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA. 2009;301:1573-9.
30. Gu W, Hu J, Wang W, Li L, Tang W, Sun S, et al. Diabetic ketoacidosis at diagnosis influences complete remission after treatment with hematopoietic stem cell transplantation in adolescents with type 1 diabetes. Diabetes Care. 2012;35:1413-9. This prospective phase 2 trial showed the safety and feasibility of intravenous autologous hematopoietic stem cell therapy in patients with T1DM.
31. Ghodsi M, Heshmat R, Amoli M, Keshtkar AA, Arjmand B, Aghayan H, et al. The effect of fetal liver-derived cell suspension allotransplantation on patients with diabetes: first year of follow-up. Acta Medica Iranica. 2012;50:541-6. This prospective randomized trial showed the safety and feasibility of intravenous alloegeneic fetal liver-derived mesechymal stem cell therapy in patients with T1DM and T2DM.
32. Jiang R, Han Z, Zhuo G, Qu X, Li X, Wang X, et al. Transplantation of placenta-derived mesenchymal stem cells in type 2 diabetes: a pilot study. Front Med. 2011;5:94-100.
33. Hu J, Yu X, Wang Z, Wang F, Wang L, Gao H, et al. Long term effects of the implantation of Wharton's jelly-derived mesenchymal stem cells from the umbilical cord for newly-onset type 1 diabetes mellitus. Endocr J. 2013;60:347-57. This double blind trial showed the safety and feasibility of intravenous allogeneic Wharton's jelly derived mesenchymal stem cell therapy in patients with T1DM.
34. Zhao Y, Jiang Z, Zhao T, Ye M, Hu C, Yin Z, et al. Reversal of type 1 diabetes via islet beta cell regeneration following immune modulation by cord blood-derived multipotent stem cells. BMC Med. 2012;10:3. This open label, phase 1/2 trial showed the safety and feasibility of intavenous autologous conditioned lymphocyte therapy in patients with T1DM.
35. Zhao Y, Jiang Z, Zhao T, Ye M, Hu C, Zhou H, et al. Targeting insulin resistance in type 2 diabetes via immune modulation of cord blood-derived multipotent stem cells (CB-SCs) in stem cell educator therapy: phase I/II clinical trial. BMC Med. 2013;11:160. This open label, phase 1/2 trial showed the safety and feasibility of intravenous autologous conditioned lymphocyte therapy in patients with T2DM.
36. Zhao Y, Wang H, Mazzone T. Identification of stem cells from human umbilical cord blood with embryonic and hematopoietic characteristics. Exp Cell Res. 2006;312:2454-64. (Pubitemid 44036799)
37. Haller MJ, Wasserfall CH, Hulme MA, Cintron M, Brusko TM, McGrail KM, et al. Autologous umbilical cord blood transfusion in young children with type 1 diabetes fails to preserve C-peptide. Diabetes Care. 2011;34(12):2567-9. This open label, randomized trial showed the safety and feasibility of intravenous autologous umbilical cord blood therapy in patients with T1DM.
38. Haller MJ, Wasserfall CH, Hulme MA, Cintron M, Brusko TM, McGrail KM, et al. Autologous umbilical cord blood infusion followed by oral docosahexaenoic acid and vitamin D supplementation for C-peptide preservation in children with Type 1 diabetes. Biol Blood Marrow Transplant. 2013;19:1126-9. This open label, randomized trial showed the safety and feasibility of intravenous autologous umbilical cord blood in combination with docosaheanoic acid and vitamin D supplementation in patients with T1DM.
39. Bhansali A, Upreti V, Khandelwal N, Marwaha N, Gupta V, Sachdeva N, et al. Efficacy of autologous bone marrow-derived stem cell transplantation in patients with type 2 diabetes mellitus. Stem Cells Dev. 2009;18:1407-16.
40. Tsai PJ, Wang HS, Lin CH, Weng ZC, Chen TH, Shyu JF. Intraportal injection of insulin-producing cells generated from human bone marrow mesenchymal stem cells decreases blood glucose level in diabetic rats. Endocr Res. 2013;39(1):26-33.
41. Carnevale G, Riccio M, Pisciotta A, Beretti F, Maraldi T, Zavatti M, et al. In vitro differentiation into insulin-producing beta-cells of stem cells isolated from human amniotic fluid and dental pulp. Dig Liver Dis. 2013;45:669-76.
42. Boroujeni Z, Aleyasin A. Human umblical cord derived mesenchymal stem cells can secret insulin in vitro and in vivo. Biotechnol Appl Biochem. 2013. doi: 10.1002/bab.1127
43. Moshtagh PR, Emami SH, Sharifi AM. Differentiation of human adipose-derived mesenchymal stem cell into insulin-producing cells: an in vitro study. J Physiol Biochem. 2013;69:451-8.
44. Kadam SS, Sudhakar M, Nair PD, Bhonde RR. Reversal of experimental diabetes in mice by transplantation of neo-islets generated from human amnion-derived mesenchymal stromal cells using immuno-isolatory macrocapsules. Cytotherapy. 2010;12:982-91.
45. Milanesi A, Lee JW, Li Z, Da Sacco S, Villani V, Cervantes V, et al. beta-Cell regeneration mediated by human bone marrow mesenchymal stem cells. PloS One. 2012;7:e42177.
46. Sun Y, Chen L, Hou XG, Hou WK, Dong JJ, Sun L, et al. Differentiation of bone marrow-derived mesenchymal stem cells from diabetic patients into insulin-producing cells in vitro. Chin Med J. 2007;120:771-6. (Pubitemid 46767823)
47. Xie QP, Huang H, Xu B, Dong X, Gao SL, Zhang B, et al. Human bone marrow mesenchymal stem cells differentiate into insulin-producing cells upon microenvironmental manipulation in vitro. Differentiation. 2009;77:483-91.
48. Dong QY, Chen L, Gao GQ, Wang L, Song J, Chen B, et al. Allogeneic diabetic mesenchymal stem cells transplantation in streptozotocin-induced diabetic rat. Clin Invest Med. 2008;31:E328-37.
49. Dave SD, Trivedi HL, Chooramani SG, Chandra T. Management of type 1 diabetes mellitus using in vitro autologous adipose tissue trans-differentiated insulin-making cells. BMJ Case Rep. 2013;2013.
50. Dave SD, Vanikar AV, Trivedi HL. Co-infusion of adipose tissue derived mesenchymal stem cell-differentiated insulin-making cells and hematopoietic cells with renal transplantation: a novel therapy for type 1 diabetes mellitus with end-stage renal disease. BMJ Case Rep. 2013;2013.
51. Trivedi HL, Thakkar UG, Vanikar AV, Dave SD. Treatment of polyglandular autoimmune syndrome type 3 using co-transplantation of insulin-secreting mesenchymal stem cells and hematopoietic stem cells. BMJ Case Rep. 2011;2011.
52. Trivedi HL, Vanikar AV, Thakker U, Firoze A, Dave SD, Patel CN, et al. Human adipose tissue-derived mesenchymal stem cells combined with hematopoietic stem cell transplantation synthesize insulin. Transplant Proc. 2008;40:1135-9. (Pubitemid 351802232)
53. Vanikar AV, Dave SD, Thakkar UG, Trivedi HL. Cotransplantation of adipose tissue-derived insulin-secreting mesenchymal stem cells and hematopoietic stem cells: a novel therapy for insulin-dependent diabetes mellitus. Stem Cells Int. 2010;2010:582382. This prospective, open label trial showed the safety and feasibility of intra-portal adipose-tissue-derived insulin-producing mesenchymal stem cell therapy in combination with unfractionated cultured bone marrow in patients with T1DM.
54. Mineo D, Ricordi C, Xu X, Pileggi A, Garcia-Morales R, Khan A, et al. Combined islet and hematopoietic stem cell allotransplantation: a clinical pilot trial to induce chimerism and graft tolerance. Am J Transplant. 2008;8:1262-74. (Pubitemid 351763683)
55. Waterman RS, Morgenweck J, Nossaman BD, Scandurro AE, Scandurro SA, Betancourt AM. Anti-inflammatory mesenchymal stem cells (MSC2) attenuate symptoms of painful diabetic peripheral neuropathy. Stem Cells Transl Med. 2012;1:557-65.
56. Park KS, Kim YS, Kim JH, Choi B, Kim SH, Tan AH, et al. Trophic molecules derived from human mesenchymal stem cells enhance survival, function, and angiogenesis of isolated islets after transplantation. Transplantation. 2010;89:509-17.
57. Lu Y, Jin X, Chen Y, Li S, Yuan Y, Mai G, et al. Mesenchymal stem cells protect islets from hypoxia/reoxygenation-induced injury. Cell Biochem Funct. 2010;28:637-43.
58. Rackham CL, Dhadda PK, Chagastelles PC, Simpson SJ, Dattani AA, Bowe JE, et al. Pre-culturing islets with mesenchymal stromal cells using a direct contact configuration is beneficial for transplantation outcome in diabetic mice. Cytotherapy. 2013;15:449-59.
59. Ito T, Itakura S, Todorov I, Rawson J, Asari S, Shintaku J, et al. Mesenchymal stem cell and islet co-transplantation promotes graft revascularization and function. Transplantation. 2010;89:1438-45.
60. Longoni B, Szilagyi E, Quaranta P, Paoli GT, Tripodi S, Urbani S, et al. Mesenchymal stem cells prevent acute rejection and prolong graft function in pancreatic islet transplantation. Diabetes Technol Ther. 2010;12:435-46.
61. Kerby A, Jones ES, Jones PM, King AJ. Co-transplantation of islets with mesenchymal stem cells in microcapsules demonstrates graft outcome can be improved in an isolated-graft model of islet transplantation in mice. Cytotherapy. 2013;15:192-200.
62. Davis NE, Beenken-Rothkopf LN, Mirsoian A, Kojic N, Kaplan DL, Barron AE, et al. Enhanced function of pancreatic islets co-encapsulated with ECM proteins and mesenchymal stromal cells in a silk hydrogel. Biomaterials. 2012;33:6691-7.
63. Kim BJ, Jin HK, Bae JS. Bone marrow-derived mesenchymal stem cells improve the functioning of neurotrophic factors in a mouse model of diabetic neuropathy. Lab Anim Res. 2011;27:171-6.
64. Shibata T, Naruse K, Kamiya H, Kozakae M, Kondo M, Yasuda Y, et al. Transplantation of bone marrow-derived mesenchymal stem cells improves diabetic polyneuropathy in rats. Diabetes. 2008;57:3099-107.
65. Wang Y, Xue M, Xuan YL, Hu HS, Cheng WJ, Suo F, et al. Mesenchymal stem cell therapy improves diabetic cardiac autonomic neuropathy and decreases the inducibility of ventricular arrhythmias. Heart Lung Circ. 2013;22(12):1018-25.
66. Chen J, Zheng S, Huang H, Huang S, Zhou C, Hou J, et al. Mesenchymal stem cells enhanced cardiac nerve sprouting via nerve growth factor in a rat model of myocardial infarction. Curr Pharm Des. 2013; in press.
67. Wei F, Wang TZ, Zhang J, Yuan ZY, Tian HY, Ni YJ, et al. Mesenchymal stem cells neither fully acquire the electrophysiological properties of mature cardiomyocytes nor promote ventricular arrhythmias in infarcted rats. Basic Res Cardiol. 2012;107:274.
68. Garcia MM, Fandel TM, Lin G, Shindel AW, Banie L, Lin CS, et al. Treatment of erectile dysfunction in the obese type 2 diabetic ZDF rat with adipose tissue-derived stem cells. J Sex Med. 2010;7(1 Pt 1):89-98.
69. Qiu X, Lin H, Wang Y, Yu W, Chen Y, Wang R, et al. Intracavernous transplantation of bone marrow-derived mesenchymal stem cells restores erectile function of streptozocin-induced diabetic rats. J Sex Med. 2011;8:427-36.
70. Ying C, Yang M, Zheng X, Hu W, Wang X. Effects of intracavernous injection of adipose-derived stem cells on cavernous nerve regeneration in a rat model. Cell Mol Neurobiol. 2013;33:233-40.
71. He Y, He W, Qin G, Luo J, Xiao M. Transplantation KCNMA1 modified bone marrow-mesenchymal stem cell therapy for diabetes mellitus-induced erectile dysfunction. Andrologia. 2013. doi: 10.1111/and.12104
72. Qiu X, Sun C, Yu W, Lin H, Sun Z, Chen Y, et al. Combined strategy of mesenchymal stem cell injection with vascular endothelial growth factor gene therapy for the treatment of diabetes-associated erectile dysfunction. J Androl. 2012;33:37-44.
73. Scalinci SZ, Scorolli L, Corradetti G, Domanico D, Vingolo EM, Meduri A, et al. Potential role of intravitreal human placental stem cell implants in inhibiting progression of diabetic retinopathy in type 2 diabetes: neuroprotective growth factors in the vitreous. Clin Ophthalmol. 2011;5:691-6.
74. Yang Z, Li K, Yan X, Dong F, Zhao C. Amelioration of diabetic retinopathy by engrafted human adipose-derived mesenchymal stem cells in streptozotocin diabetic rats. Graefe's Arch Clin Exp Ophthalmol = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 2010;248:1415-22.
75. Ezquer F, Ezquer M, Simon V, Pardo F, Yanez A, Carpio D, et al. Endovenous administration of bone-marrow-derived multipotent mesenchymal stromal cells prevents renal failure in diabetic mice. Biol Blood Marrow Transplant. 2009;15:1354-65.
76. Ezquer FE, Ezquer ME, Parrau DB, Carpio D, Yanez AJ, Conget PA. Systemic administration of multipotent mesenchymal stromal cells reverts hyperglycemia and prevents nephropathy in type 1 diabetic mice. Biol Blood Marrow Transplant. 2008;14:631-40.
77. Wang S, Li Y, Zhao J, Zhang J, Huang Y. Mesenchymal stem cells ameliorate podocyte injury and proteinuria in a type 1 diabetic nephropathy rat model. Biol Blood Marrow Transplant. 2013;19:538-46.
78. Li D, Wang N, Zhang L, Hanyu Z, Xueyuan B, Fu B, et al. Mesenchymal stem cells protect podocytes from apoptosis induced by high glucose via secretion of epithelial growth factor. Stem Cell Res Ther. 2013;4:103.
79. Lee RH, Seo MJ, Reger RL, Spees JL, Pulin AA, Olson SD, et al. Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice. Proc Natl Acad Sci U S A. 2006;103:17438-43. (Pubitemid 44788987)
80. Fang Y, Tian X, Bai S, Fan J, Hou W, Tong H, et al. Autologous transplantation of adipose-derived mesenchymal stem cells ameliorates streptozotocin-induced diabetic nephropathy in rats by inhibiting oxidative stress, pro-inflammatory cytokines and the p38 MAPK signaling pathway. Int J Mol Med. 2012;30:85-92.
81. Zhang N, Li J, Luo R, Jiang J, Wang JA. Bone marrow mesenchymal stem cells induce angiogenesis and attenuate the remodeling of diabetic cardiomyopathy. Exp Clin Endocrinol Diabetes. 2008;116:104-11. (Pubitemid 351363380)
82. Dayan V, Yannarelli G, Filomeno P, Keating A. Human mesenchymal stromal cells improve scar thickness without enhancing cardiac function in a chronic ischaemic heart failure model. Interact Cardiovasc Thorac Surg. 2012;14:516-20.
83. Khan M, Ali F, Mohsin S, Akhtar S, Mehmood A, Choudhery MS, et al. Preconditioning diabetic mesenchymal stem cells with myogenic medium increases their ability to repair diabetic heart. Stem Cell Res Ther. 2013;4:58.
84. Li JH, Zhang N, Wang JA. Improved anti-apoptotic and anti-remodeling potency of bone marrow mesenchymal stem cells by anoxic pre-conditioning in diabetic cardiomyopathy. J Endocrinol Invest. 2008;31:103-10. (Pubitemid 351596969)
85. Maharlooei MK, Bagheri M, Solhjou Z, Jahromi BM, Akrami M, Rohani L, et al. Adipose tissue derived mesenchymal stem cell (AD-MSC) promotes skin wound healing in diabetic rats. Diabetes Res Clin Pract. 2011;93:228-34.
86. Kuo YR, Wang CT, Cheng JT, Wang FS, Chiang YC, Wang CJ. Bone marrow-derived mesenchymal stem cells enhanced diabetic wound healing through recruitment of tissue regeneration in a rat model of streptozotocin-induced diabetes. Plast Reconstr Surg. 2011;128:872-80.
87. Kong P, Xie X, Li F, Liu Y, Lu Y. Placenta mesenchymal stem cell accelerates wound healing by enhancing angiogenesis in diabetic Goto-Kakizaki (GK) rats. Biochem Biophys Res Commun. 2013;438:410-9.
88. Kwon DS, Gao X, Liu YB, Dulchavsky DS, Danyluk AL, Bansal M, et al. Treatment with bone marrow-derived stromal cells accelerates wound healing in diabetic rats. Int Wound J. 2008;5:453-63. (Pubitemid 351874520)
89. O'Loughlin A, Kulkarni M, Creane M, Vaughan EE, Mooney E, Shaw G, et al. Topical administration of allogeneic mesenchymal stromal cells seeded in a collagen scaffold augments wound healing and increases angiogenesis in the diabetic rabbit ulcer. Diabetes. 2013;62:2588-94.
90. Dash NR, Dash SN, Routray P, Mohapatra S, Mohapatra PC. Targeting nonhealing ulcers of lower extremity in human through autologous bone marrow-derived mesenchymal stem cells. Rejuvenation Res. 2009;12:359-66.
91. Vojtassak J, Danisovic L, Kubes M, Bakos D, Jarabek L, Ulicna M, et al. Autologous biograft and mesenchymal stem cells in treatment of the diabetic foot. Neuro Endocrinol Lett. 2006;27 Suppl 2:134-7. (Pubitemid 46534356)
92. Shin L, Peterson DA. Impaired therapeutic capacity of autologous stem cells in a model of type 2 diabetes. Stem Cells Transl Med. 2012;1:125-35.
93. Jin P, Zhang X, Wu Y, Li L, Yin Q, Zheng L, et al. Streptozotocin-induced diabetic rat-derived bone marrow mesenchymal stem cells have impaired abilities in proliferation, paracrine, antiapoptosis, and myogenic differentiation. Transplant Proc. 2010;42:2745-52.
94. Khan M, Akhtar S, Mohsin S, Khan SN, Riazuddin S. Growth factor preconditioning increases the function of diabetes-impaired mesenchymal stem cells. Stem Cells Dev. 2011;20:67-75.
95. Amin AH, Abd Elmageed ZY, Nair D, Partyka MI, Kadowitz PJ, Belmadani S, et al. Modified multipotent stromal cells with epidermal growth factor restore vasculogenesis and blood flow in ischemic hind-limb of type II diabetic mice. Lab Invest. 2010;90:985-96.
96. Lu D, Zhang L, Wang H, Zhang Y, Liu J, Xu J, et al. Peroxisome proliferator-activated receptor-gamma coactivator-1alpha (PGC-1alpha) enhances engraftment and angiogenesis of mesenchymal stem cells in diabetic hindlimb ischemia. Diabetes. 2012;61:1153-9.
97. Lee HC, An SG, Lee HW, Park JS, Cha KS, Hong TJ, et al. Safety and effect of adipose tissue-derived stem cell implantation in patients with critical limb ischemia. Circ J. 2012;76(7):1750-60.
98. Lu D, Chen B, Liang Z, Deng W, Jiang Y, Li S, et al. Comparison of bone marrow mesenchymal stem cells with bone marrow-derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double-blind, randomized, controlled trial. Diabetes Res Clin Pract. 2011;92:26-36. This double blind, randomized controlled trial showed the safety and feasibility of either bone marrow derived mesenchymal stem cells or bone marrow derived mononuclear cell therapy in patients with T2DM and critical limb ishemia.
99. Lasala GP, Silva JA, Gardner PA, Minguell JJ. Combination stem cell therapy for the treatment of severe limb ischemia: safety and efficacy analysis. Angiology. 2010;61(6):551-6. This phase 1 trial showed the safety and feasibility of autologous bone marrow-derived endothelial progenitor cell and bone marrow-derived mesenchymal stem cell therapy for patients with diabetes mellitus and critical limb ischemia.